C5AR2/GPR77 recombinant proteins and antibodies

C5a receptor 2 (C5AR2) is a G protein-coupled receptor that plays a crucial role in the complement system, an essential part of the immune response. Upon binding to its ligand, C5a, C5AR2 activates immune cells, triggering a series of immune reactions. C5a is a key inflammatory mediator in the complement system, and its interaction with C5AR2 regulates immune and inflammatory responses. C5AR2 is expressed on various immune cells, including neutrophils, macrophages, dendritic cells, and T cells. Unlike C5a receptor 1 (C5AR1), the function of C5AR2 is more complex. While it participates in inflammatory responses, its activation can potentially alleviate certain types of inflammation by modulating immune cell functions. Therefore, C5AR2 is considered a promising immune-regulatory target, particularly in the research of chronic inflammation, autoimmune diseases, and cancer.

The role of C5AR2 in immune regulation makes it a potential target for various diseases. In autoimmune diseases, C5AR2 activation may suppress excessive immune responses, thereby alleviating the progression of inflammation. Conversely, inhibiting C5AR2 could enhance immune responses, playing an important role in certain infectious diseases. In recent years, C5AR2 has been regarded as having potential in cancer immunotherapy, particularly in improving the tumor immune microenvironment by modulating immune cell functions.

Several biopharmaceutical companies are actively developing drugs targeting C5AR2. For instance, MedImmune (a subsidiary of AstraZeneca) is developing C5AR2 antagonists for treating various diseases, including inflammatory conditions, cardiovascular diseases, and cancer. C5AR2-targeted therapies are also considered to help alleviate acute inflammatory responses, regulate immune reactions, and could be combined with other immunotherapies. Meanwhile, other biopharmaceutical companies are exploring the potential applications of C5AR2-targeted drugs in autoimmune diseases and cancer treatment. With continued research into the mechanisms of C5AR2, it is expected that more C5AR2-targeted drugs will enter clinical trials, offering new therapeutic options, particularly in immune regulation and cancer immunotherapy, with broad potential applications.

To assist in the development of C5AR2 targeted drugs, DIMA BIOTECH can now provide a series of spot products targeting C5AR2, including C5AR2 recombinant proteins, C5AR2 full-length membrane proteins, anti-C5AR2 monoclonal antibodies and biosimilar reference antibodies. At the same time, we can also provide systematic services, including protein/antibody customization services, antibody humanization, antibody affinity maturation, stable cell lines, etc. In addition, we have established a B cell seed bank targeting C5AR2, which can screen out the lead antibody molecules required by customers in just 20 days.